Ono Pharmaceutical plans to dispose of 20,900 shares and 179,000 shares of treasury stock on July 10, 2026, and allocate approximately 4.47 billion yen to shareholders and executives. The system aims for medium- to long-term corporate value enhancement and management motivation.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4528","jir_company_name":"Ono Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-06-18","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/4528-20260618-01.pdf","jir_short_summary":"Ono Pharmaceutical plans to dispose of 20,900 shares and 179,000 shares of treasury stock on July 10, 2026, and allocate approximately 4.47 billion yen to shareholders and executives. The system aims for medium- to long-term corporate value enhancement and management motivation.","jir_summary":"### Details and Purpose of Disposition\nOno Pharmaceutical will dispose of 20,900 shares of treasury stock and 179,000 shares on July 10, 2026, allocating approximately 4.47 billion yen to directors. The plan includes a stock compensation system with employment continuity and performance-linked types, aiming to promote corporate value improvement and value sharing with shareholders. The disposed shares will be priced according to the market price to ensure fairness. The introduction of this system aims at enhancing long-term corporate value.\n\n### Overview of the System and Future Outlook\nSystem I grants shares as consideration for employment continuity and job execution, with transfer restrictions during the restriction period. After the restriction expires, restrictions are\u89e3\u9664 and, upon resignation or retirement, shares are acquired free of charge or restrictions are\u89e3\u9664. System II is performance-linked, providing shares or cash based on performance evaluations. These systems aim to enhance long-term corporate value and shareholder value sharing, with ongoing operation and improvements expected in the future.","jir_financial_highlights":"Number of Shares Disposed: 20,900 shares (Employment Continuity Type) (Unknown)\nNumber of Shares Disposed: 179,000 shares (Performance-Linked Type) (Unknown)\nTotal Disposition Amount: Approximately 4.47 billion yen (Unknown)","jir_category":"","jir_hashtags":"#OnoPharmaceutical, #IRRelated, #JapanStocks","jir_key_figures":"Number of Shares Disposed: 20,900 shares (Employment Continuity Type)\nNumber of Shares Disposed: 179,000 shares (Performance-Linked Type)\nTotal Disposition Amount: Approximately 4.47 billion yen","jir_meta_title":"[Ono Pharmaceutical] Share Buyback and Employee Stock Compensation System Introduction | June 2026","jir_meta_description":"Ono Pharmaceutical plans to dispose of approximately 4.47 billion yen worth of treasury stock in July 2026 and will allocate it to executives. Details of the background and future outlook of the system are provided.","jir_og_title":"[Ono Pharmaceutical] Share Buyback and Employee Stock Compensation | June 2026","jir_og_description":"Ono Pharmaceutical introduces share buyback and employee stock compensation system to enhance corporate value and shareholder value sharing.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7530,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_cancellation","footnotes":""},"sector":[],"importance":[],"class_list":["post-65915","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n